Biotricity, Inc. (BTCY)

USD 0.5

(2.04%)

Total Liabilities Summary of Biotricity, Inc.

Biotricity, Inc.'s latest annual total liabilities in 2024 was 35.91 Million USD , up 36.29% from previous year.
Biotricity, Inc.'s latest quarterly total liabilities in 2024 FY was 35.91 Million USD , up 36.29% from previous quarter.
Biotricity, Inc. reported annual total liabilities of 26.35 Million USD in 2023, up 40.02% from previous year.
Biotricity, Inc. reported annual total liabilities of 18.82 Million USD in 2022, up 67.0% from previous year.
Biotricity, Inc. reported quarterly total liabilities of 29.55 Million USD for 2024 Q1, up 12.14% from previous quarter.
Biotricity, Inc. reported quarterly total liabilities of 35.91 Million USD for 2024 FY, up 36.29% from previous quarter.

Annual Total Liabilities Chart of Biotricity, Inc. (2024 - 2014)

Historical Annual Total Liabilities of Biotricity, Inc. (2024 - 2014)

Year	Total Liabilities	Total Liabilities Growth
2024	35.91 Million USD	36.29%
2023	26.35 Million USD	40.02%
2022	18.82 Million USD	67.0%
2021	11.27 Million USD	125.21%
2020	5 Million USD	120.64%
2019	2.26 Million USD	199.97%
2018	756.17 Thousand USD	-84.44%
2017	4.85 Million USD	176.31%
2016	1.75 Million USD	570.27%
2015	262.32 Thousand USD	53.8%
2014	170.56 Thousand USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q4	35.91 Million USD	11.5%
2024 Q1	29.55 Million USD	12.14%
2024 FY	35.91 Million USD	36.29%
2024 Q3	32.21 Million USD	-0.25%
2024 Q2	32.29 Million USD	9.27%
2023 Q2	18.67 Million USD	-0.18%
2023 FY	26.35 Million USD	40.02%
2023 Q4	26.35 Million USD	19.1%
2023 Q3	22.12 Million USD	18.48%
2023 Q1	18.71 Million USD	-0.6%
2022 Q4	18.82 Million USD	0.51%
2022 FY	18.82 Million USD	67.0%
2022 Q3	18.72 Million USD	201.69%
2022 Q2	6.2 Million USD	-53.56%
2022 Q1	13.36 Million USD	18.59%
2021 FY	11.27 Million USD	125.21%
2021 Q1	6.37 Million USD	27.36%
2021 Q3	15.84 Million USD	67.15%
2021 Q4	11.27 Million USD	-28.88%
2021 Q2	9.48 Million USD	48.73%
2020 Q3	7.44 Million USD	24.95%
2020 Q1	4.31 Million USD	90.11%
2020 Q4	5 Million USD	-32.75%
2020 FY	5 Million USD	120.64%
2020 Q2	5.95 Million USD	38.11%
2019 FY	2.26 Million USD	199.97%
2019 Q2	1.04 Million USD	4.12%
2019 Q1	1 Million USD	33.1%
2019 Q4	2.26 Million USD	71.35%
2019 Q3	1.32 Million USD	26.33%
2018 Q2	762.8 Thousand USD	-84.05%
2018 FY	756.17 Thousand USD	-84.44%
2018 Q4	756.17 Thousand USD	20.01%
2018 Q3	630.08 Thousand USD	-17.4%
2018 Q1	4.78 Million USD	-1.58%
2017 FY	4.85 Million USD	176.31%
2017 Q1	3.77 Million USD	38.46%
2017 Q2	2.59 Million USD	-31.27%
2017 Q3	4.13 Million USD	59.24%
2017 Q4	4.85 Million USD	17.46%
2016 Q1	262.18 Thousand USD	0.0%
2016 Q2	262.32 Thousand USD	0.05%
2016 Q3	1.75 Million USD	570.27%
2016 Q4	2.72 Million USD	55.24%
2016 FY	1.75 Million USD	570.27%
2015 FY	262.32 Thousand USD	53.8%
2015 Q2	170.56 Thousand USD	0.0%
2014 FY	170.56 Thousand USD	0.0%

Peer Total Liabilities Comparison of Biotricity, Inc.

Name	Total Liabilities	Total Liabilities Difference
Acutus Medical, Inc.	54.83 Million USD	34.5%
Cell MedX Corp.	872.57 Thousand USD	-4016.478%
Dynatronics Corporation	11.78 Million USD	-204.916%
Nemaura Medical Inc.	26.37 Million USD	-36.175%
PetVivo Holdings, Inc.	2.42 Million USD	-1378.592%
RetinalGenix Technologies Inc.	1.4 Million USD	-2455.065%
Sonendo, Inc.	49.74 Million USD	27.787%
Telesis Bio, Inc.	40.87 Million USD	12.119%
Talis Biomedical Corporation	29.22 Million USD	-22.911%
Viveve Medical, Inc.	10.84 Million USD	-231.146%